AEM vs AMTX

AEM's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability, while the absence of an Altman Z-Score limits distress risk assessment. Despite strong profitability metrics—ROE of 15.67%, gross margin of 70.24%, and robust earnings growth of 85.8% YoY—the stock trades at a premium valuation (P/E 31.23 vs sector avg 25.89) above both the Graham Number ($85.07) and intrinsic value estimate ($202.66). Strong recent price performance (+145% 1Y) and analyst buy recommendation are counterbalanced by weak technical trend (10/100) and limited insider sentiment (40/100). The balance between operational strength and valuation concerns leads to a neutral stance.

AMTX exhibits weak financial health with a Piotroski F-Score of 4/9, indicating a fragile operational foundation. The absence of an Altman Z-Score and negative profitability metrics—especially a -38.96% profit margin and -8.96% ROA—signal severe operational distress. Despite a 14.2% YoY revenue growth and recent positive EPS surprises, the company remains unprofitable with negative cash flow and extreme liquidity issues (current ratio of 0.07). The stock trades at a price/sales of 0.77, but this is misleading given the lack of sustainable earnings and deteriorating balance sheet. The 52-week price range of $1.22–$3.66 reflects high volatility and speculative risk.